15
Contraindications and Cautions
Sulfasalazine tablets are contraindicated in patients with intestinal or urinary
obstruction, patients with porphyria and patients hypersensitive to sulfasalazine, its
metabolites, sulfonamides, or salicylates.
Only aer critical appraisal should sulfasalazine tablets be given to patients
with hepatic or renal damage or blood dyscrasias. Deaths associated with the
administration of sulfasalazine have been reported from hypersensitivity reactions,
agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage,
irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis.
Sulfasalazine tablets should be given with caution to patients with severe allerg y or
bronchial asthma. Adequate fluid intake must be maintained to prevent crystalluria and
stone formation. Patients with glucose-6 phosphate dehydrogenase deficiency should
be observed closely for signs of hemolytic anemia. If toxic or hypersensitivity reactions
occur, the drug should be discontinued immediately
No contraindications.
Warning that serious infections leading to hospitalization or death, including TB and
bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in
patients receiving tofacitinib.
Table A4. Commonly Conducted Testing During irAE
Management With Steroids*
Clinical
Physical examination including blood pressure, weight, heart rate, SPO
2
Assess for presence of infection including oral Candida
Screen for classic symptoms of hyperglycemia/diabetes: polyuria, polydipsia, weight loss
Eye examination, including assessment of increased intraocular pressure with therapy
>6 weeks
Laboratory
Complete CBC + DIFF
Complete metabolic panel that may include serum electrolytes (Na, K, Ca, CO
2
), liver
function (AST, ALT, ALKP, GGT), creatinine, CK, total bilirubin, glucose
Imaging
Bone mineral density (during prolonged therapy)
* Other testing may also be necessary, based on patient's history and pre-existing comorbidities and/
or risk factors.
